After the first FDA‐approval of CGM for DM management in 1999, CGM systems are now routinely used by patients with insulin dependent DM, with recommendations for their use included in major guidelines and consensus statements [14, 15, 16, 17]. The gene discussed is INS; the disease is diabetes mellitus.